According to Zhito Finance APP, Aurora Mobile-B (06681) will conduct its initial public offering from December 30, 2024, to January 3, 2025. The company plans to globally offer approximately 0.181 billion shares, with 10% allocated for public sale in Hong Kong and 90% for international sale, along with an over-allotment option of 15%. The offering price per share is set at HKD 3.22, with a minimum purchase of 1000 shares. The shares are expected to begin trading on the Hong Kong Stock Exchange at 9:00 AM on January 8, 2025 (Wednesday).

In addition, the company has signed cornerstone investment agreements with Tasly Pharmaceutical Group (Hong Kong), Tasly Pharmaceutical Group (International), Huang Guangwei, and Suzhou Ceyuan. Assuming the offering price is HKD 3.22, the total amount of shares to be subscribed by cornerstone investors is around USD 48.5 million, involving about 0.1164 billion shares, which accounts for approximately 64.27% of the global offering and 9.19% of the shares after the global offering completion and share subdivision (assuming the over-allotment option is not exercised).

Assuming the over-allotment option is not exercised, the net proceeds from the global offering are expected to be approximately HKD 0.5013 billion, calculated at the offering price of HKD 3.22 per share. About 40.0% is expected to be used for further research and development activities, advancing clinical trials for more indications, and promoting sales and distribution activities of core product systems; approximately 16.5% is anticipated to help more hospitals in China establish new cognition centers, through which hospitals can use the company's products to diagnose and treat cognitive disorders and/or other conditions; about 15.0% is likely to strengthen the company's AI and related technical capabilities; 5.0% is expected to be used to accelerate the research and commercialization progress of other candidate products within and outside the existing product pipeline; about 15.0% is anticipated to be used for brain science and digital therapy research centers in collaboration with academic institutions and hospitals; and about 8.5% is expected to be allocated for working capital and other general corporate purposes.

It is reported that the company was established in 2012. The product pipeline covers a wide range of cognitive impairments induced by vascular diseases, neurodegenerative diseases, mental illnesses, and developmental disorders in children. As of the last feasible date, the company's core product - the brain function information management platform Software system has been commercialized for eight indications related to four major types of cognitive impairments and is currently developing other indications for cognitive disorders. As of the last feasible date, the company has three additional products that have obtained regulatory approval in China (namely the Basic Cognitive Ability Test Software (BCAT), the Cognitive Ability Assisted Screening Assessment Software (SAS), and the Dyslexia Assisted Screening Assessment Software (DSS)), and one product has received regulatory approval in the European Union (namely the Cognitive Dysfunction Treatment Software), while six candidate products are at different stages of preclinical and clinical development or registration process. The company holds rights over its products and candidate products in jurisdictions where regulatory approval has been obtained.

From 2021 to 2023, the company achieved revenues of HKD 2.299 million, HKD 11.291 million, and HKD 67.2 million respectively, with losses attributable to shareholders of approximately HKD 0.698 billion, HKD 0.502 billion, and HKD 0.359 billion. In the first half of 2024, the company achieved revenue of approximately HKD 51.887 million, with losses attributable to shareholders of around HKD 0.114 billion.